Received May 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Hepatitis A vaccine was given couple months too soon to a patient about an year ago; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of drug dose administration interval too short in a patient who received HAV (Havrix) for prophylaxis. Previously administered products included Havrix (received 1st dose on an unknown date). On an unknown date, the patient received the 2nd dose of Havrix. On an unknown date, an unknown time after receiving Havrix, the patient experienced drug dose administration interval too short (Verbatim: Hepatitis A vaccine was given couple months too soon to a patient about an year ago). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 20-MAY-2025 The reporter called to state that the Hepatitis A vaccine was given couple months too soon to a patient about a year ago which led to drug dose administration interval too short. Upon clarification, the reporter stated that the product was Havrix and not VAQTA. The reporter stated that she would call the corresponding manufacturer.